IH Drug Candidate Tolerated Across Doses, Interim Data Shows

Interim data from a phase 2 trial of KP1077 in patients with IH indicates the drug is well-tolerated at all tested doses and dosing schedules.

Related Keywords

Rene Braeckman , , Zevra Therapeutic ,